The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia

The guideline focuses specifically on evidence-based pharmacological and nonpharmacological treatments for schizophrenia and includes statements related to assessment and treatment planning, which are an integral part of patient-centered care. The guideline provides direction on implementing these r...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Association, American Psychiatric
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Washington, D.C. : American Psychiatric Association Publishing, 2020.
Edición:3rd ed.
Temas:
Schizophrenia > Treatment.
Schizophrenia > therapy
Schizophrénie > Traitement.
Schizophrenia > Treatment
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Cover
  • Title
  • Copyright
  • Contents
  • Acronyms/Abbreviations
  • Introduction
  • Rationale
  • Scope of Document
  • Overview of the Development Process
  • Rating the Strengths of Guideline Statements and Supporting Research Evidence
  • Proper Use of Guidelines
  • Guideline Statement Summary
  • Guideline Statements and Implementation
  • Assessment and Determination of Treatment Plan
  • Statement 1: Assessment of Possible Schizophrenia
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 2: Use of Quantitative Measures
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 3: Evidence-Based Treatment Planning
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Pharmacotherapy
  • Statement 4: Antipsychotic Medications
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 5: Continuing Medications
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 6: Continuing the Same Medications
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 7: Clozapine in Treatment-Resistant Schizophrenia
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 8: Clozapine in Suicide Risk
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 9: Clozapine in Aggressive Behavior
  • Implementation
  • Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement
  • Review of Available Guidelines From Other Organizations
  • Quality Measurement Considerations
  • Statement 10: Long-Acting Injectable Antipsychotic Medications
  • Implementation

Ejemplares similares